Woodline Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Woodline Partners’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$66M	Buy	758,891 +70,112	+10%	+$6.82M	0.25%	92
2025 Q4	$73.7M	Buy	688,779 +108,596	+19%	+$11.5M	0.29%	76
2025 Q3	$58.6M	Buy	580,183 +65,802	+13%	+$6.11M	0.28%	85
2025 Q2	$32.5M	Buy	+514,381	New	+$31.5M	0.17%	169
2024 Q4	–	Sell	-143,823	Closed	-$7.53M	–	987
2024 Q3	$7.53M	Buy	143,823 +99,576	+225%	+$4.77M	0.06%	338
2024 Q2	$1.82M	Sell	44,247 -127,960	-74%	-$5.11M	0.02%	427
2024 Q1	$7.46M	Buy	172,207 +97,357	+130%	+$4.26M	0.07%	312
2023 Q4	$3.44M	Buy	+74,850	New	+$2.36M	0.04%	349

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Woodline Partners's RYTM Position: Q1 2026 in Review

Woodline Partners increased its Rhythm Pharmaceuticals (RYTM) stake by 10% in Q1 2026, buying an estimated $6.82M and bringing the position to 758,891 shares worth $66M. The position accounts for 0.25% of the portfolio, ranked #92.

Woodline Partners first reported a position in RYTM in Q4 2023 and has held it in 8 quarters since. The position peaked at $73.7M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Woodline Partners held 758,891 shares of Rhythm Pharmaceuticals worth $66M as of Q1 2026.
Woodline Partners bought 70,112 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $6.82M.
Rhythm Pharmaceuticals made up 0.25% of Woodline Partners's portfolio in Q1 2026, its #92 holding.
Woodline Partners first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Woodline Partners's Rhythm Pharmaceuticals position peaked at $73.7M in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.